Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 16/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.80 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.80 |
| ▸ | ABL2 | P42684 | 2/20 | 0.80 |
| ▸ | CSF1R | P07333 | 2/20 | 0.80 |
| ▸ | GAK | O14976 | 1/20 | 0.80 |
| ▸ | MLNR | O43193 | 1/20 | 0.80 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.80 |
| ▸ | JAK2 | O60674 | 1/20 | 0.80 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.80 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.80 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.80 |
| ▸ | EGFR | P00533 | 1/20 | 0.80 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.80 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.80 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.80 |
| ▸ | LCK | P06239 | 1/20 | 0.80 |
| ▸ | FYN | P06241 | 1/20 | 0.80 |
| ▸ | PGR | P06401 | 1/20 | 0.80 |
| ▸ | YES1 | P07947 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31697365 | 1.00 | ABL1 (0.80) | ABL1CYP3A4KCNH2ABL2CSF1R | |
| SCHEMBL29888993 | 0.94 | ABL1 (0.78) | ABL1CYP3A4KCNH2ABL2CSF1R | |
| SCHEMBL18298081 | 0.94 | ABL1 (0.78) | ABL1CYP3A4KCNH2ABL2CSF1R | |
| SCHEMBL16241445 | 0.94 | ABL1 (0.78) | ABL1CYP3A4KCNH2ABL2CSF1R | |
| SCHEMBL16250614 | 0.93 | ABL1 (0.80) | ABL1CYP3A4KCNH2ABL2CSF1R | |
| SCHEMBL18298087 | 0.91 | ABL1 (0.74) | ABL1CYP3A4KCNH2ABL2CSF1R | |
| SCHEMBL15061740 | 0.91 | ABL1 (0.74) | ABL1CYP3A4KCNH2ABL2CSF1R | |
| SCHEMBL15144985 | 0.90 | ABL1 (0.89) | ABL1CYP3A4KCNH2ABL2CSF1R | |
| SCHEMBL20143350 | 0.90 | ABL1 (0.91) | ABL1CYP3A4KCNH2ABL2CSF1R | |
| SCHEMBL25756905 | 0.90 | ABL1 (0.72) | ABL1CYP3A4KCNH2ABL2CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988389-B2 | Processes for making ponatinib and intermediates thereof | APICORE US LLC (US) | 2018-06-05 | — | — | US | claimed |
| US-20180044345-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | MYLAN API US LLC | 2018-02-15 | — | — | US | claimed |
| US-20160362411-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | MYLAN API US LLC | 2016-12-15 | — | — | US | claimed |
| WO-2016201203-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | APICORE US LLC (US) | 2016-12-15 | — | — | WO | claimed |
| US-12440494-B2 | Compounds useful for inhibiting RAF dimers | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2025-10-14 | — | — | US | disclosed |
| US-20220265669-A1 | COMPOUNDS USEFUL FOR INHIBITING RAF DIMERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-08-25 | — | — | US | disclosed |
| US-20220265669-A1 | COMPOUNDS USEFUL FOR INHIBITING RAF DIMERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-08-25 | — | — | US | disclosed |
| US-9988389-B2 | Processes for making ponatinib and intermediates thereof | APICORE US LLC (US) | 2018-06-05 | — | — | US | disclosed |
| US-9988389-B2 | Processes for making ponatinib and intermediates thereof | APICORE US LLC (US) | 2018-06-05 | — | — | US | disclosed |
| US-20180044345-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | MYLAN API US LLC | 2018-02-15 | — | — | US | disclosed |
| US-20180044345-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | MYLAN API US LLC | 2018-02-15 | — | — | US | disclosed |
| WO-2016201203-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | APICORE US LLC (US) | 2016-12-15 | — | — | WO | disclosed |
| US-20160362411-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | MYLAN API US LLC | 2016-12-15 | — | — | US | disclosed |
| US-20160362411-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | MYLAN API US LLC | 2016-12-15 | — | — | US | disclosed |
| WO-2016201203-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | APICORE US LLC (US) | 2016-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220265669-A1 | COMPOUNDS USEFUL FOR INHIBITING RAF DIMERS | BRAF, RAF1, NRAS | ABL1 544/4885CYP3A4 3303/4885KCNH2 2753/4885 |
| US-20180044345-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | ABL1, KRAS, ROS1 | ABL1 1/4885CYP3A4 28/4885KCNH2 2441/4885 |
| US-20160362411-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | ABL1, KRAS, ROS1 | ABL1 1/4885CYP3A4 28/4885KCNH2 2441/4885 |
| US-12440494-B2 | Compounds useful for inhibiting RAF dimers | BRAF, RAF1, NRAS | ABL1 547/4885CYP3A4 3301/4885KCNH2 2797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.